Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.56 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.55 |
| ▸ | FEN1 | P39748 | 5/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205371 | 0.88 | ALOX5AP (0.51) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL19205402 | 0.88 | ALOX5AP (0.54) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL19205333 | 0.88 | ALOX5AP (0.54) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL19205332 | 0.88 | ALOX5AP (0.54) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL19205390 | 0.87 | RBP4 (0.54) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL19205388 | 0.87 | RBP4 (0.54) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL31330761 | 0.87 | RBP4 (0.58) | RBP4ALOX5APFEN1SCN9ABRD3 | |
| SCHEMBL19205323 | 0.86 | ALOX5AP (0.56) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL19205324 | 0.86 | ALOX5AP (0.56) | RBP4ALOX5APFEN1PTGDR2SCN9A | |
| SCHEMBL19205444 | 0.85 | RBP4 (0.58) | RBP4ALOX5APFEN1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | RBP4 1/4885ALOX5AP 2617/4885FEN1 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.